Number of the records: 1  

In vitro study of 2,3-dehydrosilybin and its galloyl esters as potential inhibitors of angiogenesis

  1. 1.
    SYSNO ASEP0465585
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleIn vitro study of 2,3-dehydrosilybin and its galloyl esters as potential inhibitors of angiogenesis
    Author(s) Pivodová, V. (CZ)
    Zahler, S. (DE)
    Karas, D. (CZ)
    Valentová, Kateřina (MBU-M) RID, ORCID
    Ulrichová, J. (CZ)
    Source TitlePharmazie. - : Avoxa - ISSN 0031-7144
    Roč. 71, č. 8 (2016), s. 478-483
    Number of pages6 s.
    Languageeng - English
    CountryDE - Germany
    KeywordsNF-KAPPA-B ; VASCULAR ENDOTHELIAL-CELLS ; GROWTH-FACTOR
    Subject RIVEE - Microbiology, Virology
    R&D ProjectsGA15-03037S GA ČR - Czech Science Foundation (CSF)
    Institutional supportMBU-M - RVO:61388971
    UT WOS000385261200009
    EID SCOPUS84989864018
    Annotation2,3-Dehydrosilybin exhibits substantial anticancer and antiangiogenic effects, which can be potentially improved by semi-synthetic modification such as esterification with gallic acid. The aim of this study was to examine the potential antiangiogenic effect of 2,3-dehydrosilybin and its galloyl esters (3-O-galloyl-2,3-dehydrosilybin; 7-O-galloyl-2,3-dehydrosilybin; 20-O-galloyl-2,3-dehydrosilybin and 23-O-galloyl-2,3-dehydrosilybin) and to determine which molecular mechanism could be responsible for their activity. The effect on cell proliferation, tube formation, signal transduction pathways (PI3K/Akt and ERK) and the cell cycle was studied in human microvascular endothelial cells (HMEC). The results showed that all compounds decreased the growth of HMEC, but the strongest effect was observed for 20-O-galloyl-2,3-dehydrosilybin at 5 mu mol/l. In addition, at 5 and 10 mu mol/l, this was the only compound that significantly inhibited HMEC tube formation. Based on an assessment of Akt and ERK1/2 expression, we suggest that 20-O-galloyl-2,3-dehydrosilybin influences the angiogenic process through the Akt pathway.
    WorkplaceInstitute of Microbiology
    ContactEliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231
    Year of Publishing2017
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.